Home / Peptides / Tesamorelin

Tesamorelin Dosage Chart and Schedule

FDA-approved

GHRH analogue (Egrifta) approved for HIV-associated abdominal fat. Egrifta WR: 1.28 mg daily.

Also called: Egrifta, Egrifta SV, Egrifta WR

Regulatory status (US)

FDA-approved since 2010 (Egrifta) to reduce excess abdominal fat in adults with HIV and lipodystrophy. Egrifta WR replaced Egrifta SV in 2025. It has no approved use for general fat loss or anti-aging.

What it is

A synthetic version of growth-hormone-releasing hormone (GHRH) that makes the pituitary release growth hormone, which raises IGF-1.

Label doses

ProductDaily doseHow it is mixed
Egrifta WR (11.6 mg vial)1.28 mg under the skin once daily1.3 mL bacteriostatic water per the label; one vial lasts 7 days
Egrifta SV (2 mg vial)1.4 mg once dailyOlder product, replaced by WR

From the Egrifta labels. The products are not interchangeable mg for mg; follow the instructions for the exact product.

Tesamorelin reconstitution calculator

Enter your vial and your prescribed dose to see the units on a U-100 syringe.

–
Concentration–
Per 1 unit (0.01 mL)–
Volume per dose–
Doses per vial–

What human studies show

Storage

Safety

Questions

Is Tesamorelin FDA-approved?
FDA-approved since 2010 (Egrifta) to reduce excess abdominal fat in adults with HIV and lipodystrophy. Egrifta WR replaced Egrifta SV in 2025. It has no approved use for general fat loss or anti-aging.
What dose of Tesamorelin has been studied?
Egrifta WR (11.6 mg vial): 1.28 mg under the skin once daily: 1.3 mL bacteriostatic water per the label; one vial lasts 7 days; Egrifta SV (2 mg vial): 1.4 mg once daily: Older product, replaced by WR. From the Egrifta labels. The products are not interchangeable mg for mg; follow the instructions for the exact product.
How many units is my Tesamorelin dose?
Divide the mg in the vial by the mL of bacteriostatic water to get mg/mL, divide your dose in mg by that, and multiply by 100 for units on a U-100 syringe. The calculator on this page does it and draws the syringe.

Related

Tirzepatide

Weekly GIP and GLP-1 agonist (Mounjaro, Zepbound). Label: 2.5 mg start, +2.5 mg every 4 weeks, max 15 mg.

Semaglutide

Weekly GLP-1 agonist (Ozempic, Wegovy). Wegovy label: 0.25 mg start, up to 2.4 mg, or 7.2 mg (HD).

Orforglipron (Foundayo)

Daily GLP-1 pill from Lilly (Foundayo), approved April 2026. Not a peptide and never reconstituted.

Elamipretide (SS-31)

Mitochondria-targeted peptide (Forzinity), approved 2025 only for Barth syndrome. Label: 40 mg daily.

Sources

  1. DailyMed: Egrifta (tesamorelin) labeling
  2. FDA label: Egrifta WR (tesamorelin) 2025
  3. FDA 510(k) K212499: BD insulin syringes for U-100 insulin

Last checked 2026-11-16. How we pick and check sources: methodology.